Cocrystal Pharma, Inc. has made significant updates to its stock ownership structure, as detailed in a recent SEC filing. This change is notable for the company as it reflects adjustments in the holdings of its key stakeholders, which may impact corporate governance and shareholder dynamics.
Background
Cocrystal Pharma, Inc. is a pharmaceutical company focused on developing novel antiviral therapeutics. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Cocrystal Pharma trades on the Nasdaq under the ticker symbol COCP.
What the Filing Says
The recent filing, an amendment to Schedule 13D, was made on November 6, 2026. It updates the ownership information for key stakeholders in Cocrystal Pharma, including OPKO Health, Inc., Frost Gamma Investments Trust, and Phillip Frost, M.D. The filing states, "This Amendment is being filed to correct the reported ownership information for certain Reporting Persons." It clarifies the stakes held by these entities, indicating that OPKO owns approximately 29.6% of Cocrystal's common stock, while Frost Gamma Investments Trust and Dr. Frost hold around 13.6% and 13.9%, respectively.
Impact
This update may affect various stakeholders, including shareholders and potential investors, as it clarifies the ownership structure and the influence of major shareholders on company decisions. The filing also indicates that certain reporting persons disclaim beneficial ownership of securities held by others, which could influence shareholder perceptions and company governance.
What's Next
The filing does not say what happens next.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




